Ipamorelin Regulatory Status: Compounding Access in 2026

A plain-language look at where ipamorelin sits with the FDA, and what its compounding status means for access.

TL;DR

The FDA (Food and Drug Administration) removed ipamorelin from 503A Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. At its October 29, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin to the 503A bulks list. Ipamorelin is not FDA-approved, and no compounded version is FDA-approved.

What ipamorelin regulatory status means today

Ipamorelin is not in any FDA 503A category today. The FDA sorts nominated bulk substances into categories. Category 2 is the flagged bucket: the agency has significant questions about compounding a substance from raw powder. The FDA placed ipamorelin in Category 2 during its review of nominated bulk substances (FDA, 2023). FDA removed ipamorelin from Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, ipamorelin is not on the 503A bulks list either. A 503A pharmacy is a state-licensed pharmacy that makes patient-specific medicines. Ipamorelin is still in Category 2 on FDA's separate list for 503B outsourcing facilities.

How the category system works

The category system is the FDA's way of deciding what compounding pharmacies may use. Think of it like a guest list at a door. Category 1 substances may go in; Category 2 substances are held back pending review. Ipamorelin was on the held-back list until September 27, 2024. As of September 14, 2026, it is not in any 503A category. Category 2 was a compounding-access decision, not a criminal ban on the molecule itself.

Who asks about this

People considering growth hormone secretagogue peptides ask about ipamorelin's status most often. A growth hormone secretagogue (in plain English: a compound studied for prompting the body's own growth hormone release) draws interest, but interest does not equal access. The regulatory answer comes before any clinical conversation.

What could change

In February 2026, HHS (Department of Health and Human Services) Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. Ipamorelin was not part of that April 2026 change, because FDA had already removed it from Category 2 in September 2024. At its October 29, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin to the 503A bulks list. Ipamorelin was not on the agenda of the committee's July 23–24, 2026 meeting.

The Halftime POV

We follow the rules as written, not as we wish them. Right now, ipamorelin is not in any 503A category and is not on the 503A bulks list.

Related reading:

• Why Some Peptides Are Still Category 2
• The April 2026 FDA Reclassification Path
• The Three-Category Access Model
• Sermorelin Regulatory Status

FAQ

Is ipamorelin legal? Ipamorelin is not a controlled substance. FDA removed ipamorelin from Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list.

Is ipamorelin FDA approved? No. Ipamorelin is not FDA-approved for any use, and no compounded version is FDA-approved. It has been studied as a growth hormone secretagogue, but it has not gone through FDA approval as a marketed medicine.

Can you still get ipamorelin from a compounding pharmacy? FDA removed ipamorelin from 503A Category 2 on September 27, 2024. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. At its October 29, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin to the 503A bulks list. Ipamorelin was not on the agenda of the committee's July 23–24, 2026 meeting.

What does Category 2 mean for ipamorelin? Category 2 means the FDA flagged safety questions about compounding a substance from bulk powder. Ipamorelin was in 503A Category 2 until FDA removed it on September 27, 2024. It is still in Category 2 on FDA's separate list for 503B outsourcing facilities.

Disclaimer

Several peptides discussed in this article — including ipamorelin — were previously in FDA's Category 2. FDA removed them from Category 2 on September 27, 2024. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

Get started with Halftime Health.

Sources

• FDA, Human Drug Compounding Q&A: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca